OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Subscription and Copyright Information	761
Subscription and Copyright Information	490
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	327
Subscription and Copyright Information	199
Subscription and Copyright Information	177
Advisory Board and Contents	177
Subscription and Copyright Information	172
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	160
Peptides as a therapeutic strategy against Klebsiella pneumoniae	151
Muscarinic receptors: from clinic to bench to clinic	144
Shearing of surface mucin saps tumor cell strength	139
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	123
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	117
Structural asymmetry in FGF23 signaling	116
Compstatins: the dawn of clinical C3-targeted complement inhibition	110
Structural pharmacology and mechanisms of GLP-1R signaling	104
Targeting complement in neurodegeneration: challenges, risks, and strategies	104
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	102
Therapeutic inhibition of ferroptosis in neurodegenerative disease	97
Direct in vivo CAR T cell engineering	93
Advisory Board and Contents	90
Advisory Board and Contents	89
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	84
Phenotypic approaches for CNS drugs	83
A smart hospital-driven approach to precision pharmacovigilance	83

Nemolizumab (Nemluvio®) for prurigo nodularis	75
Emerging strategies for beta cell transplantation to treat diabetes	75
HSV-1 as a gene delivery platform for cancer gene therapy	74
Advisory Board and Contents	73
A deep dive into degrader-induced protein-protein interfaces	72
Optogenetic engineering for precision cancer immunotherapy	66
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	65
Ribosome-directed cancer therapies: the tip of the iceberg?	64
Leveraging human microbiomes for disease prediction and treatment	64
A perspective on psychedelic teratogenicity: the utility of zebrafish models	64
Engineering ACE2 decoy receptors to combat viral escapability	63
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	62
Genetically engineered loaded extracellular vesicles for drug delivery	60
siRNA drug Leqvio (inclisiran) to lower cholesterol	60
Advisory Board and Contents	59
Advancing non-destructive analysis of 3D printed medicines	59
Suzetrigine for moderate to severe acute pain	59
The structure, function, and pharmacology of MRGPRs	58
Close to a year in TIPS’ saddle – I am optimistic	57
Subscription and Copyright Information	56
Thriving as members of under-represented groups in pharmacology-related careers	54
Lipoxygenases in chronic liver diseases: current insights and future perspectives	51
Mentoring future science leaders to thrive	50
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	50
Emerging approaches to induce immune tolerance to therapeutic proteins	49
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	49